Cimicoxib
![]() | |
| Names | |
|---|---|
| IUPAC name
4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide | |
| Identifiers | |
| 265114-23-6 | |
| ChEBI | CHEBI:76127 |
| ChEMBL | ChEMBL435381 |
| ChemSpider | 184745 |
| Jmol 3D model | Interactive image |
| PubChem | 213053 |
| |
| |
| Properties | |
| C16H13ClFN3O3S | |
| Molar mass | 381.81 g·mol−1 |
| Pharmacology | |
| QM01AH93 (WHO) | |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Cimicoxib (UR-8880 trade name Cimalgex) is a non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine to treat dogs for pain and inflammation associated with osteoarthritis and for the management of pain and inflammation associated with surgery.[1] It acts as a COX-2 inhibitor.
References
- ↑ "European Public Assessment Report: Cimalgex (cimicoxib)". European Medicines Agency.
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
